Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Junyi Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7214-8448; OpenAlex author ID A5101403131. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 2 papers

Papers 9

  1. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Co-author DOI 10.1016/j.canlet.2024.217289↗
  2. An iron-containing nanomedicine for inducing deep tumor penetration and synergistic ferroptosis in enhanced pancreatic cancer therapy. Co-author DOI 10.1016/j.mtbio.2024.101132↗
  3. Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and lit… First author DOI 10.21037/gs-22-6↗
  4. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.968610↗
  5. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Co-author DOI 10.1007/s00262-020-02816-0↗
  6. The promoting effects of hsa_circ_0050102 in pancreatic cancer and the molecular mechanism by targeting miR-1182/NPSR1. First author DOI 10.1093/carcin/bgaa130↗
  7. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.774435↗
  8. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  9. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.15856↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quan Liao · 6 shared papers, 2020–2022 · strength 0.79
  2. Surong Hua · 4 shared papers, 2021–2024 · strength 0.72
  3. Ming Cui · 5 shared papers, 2020–2024 · strength 0.69
  4. Tong Li · 5 shared papers, 2020–2024 · strength 0.65
  5. Qiaofei Liu · 4 shared papers, 2020–2024 · strength 0.62
  6. Yalu Zhang · 4 shared papers, 2021–2024 · strength 0.61
  7. Mengyi Wang · 4 shared papers, 2020–2022 · strength 0.59
  8. Sen Yang · 3 shared papers, 2021–2024 · strength 0.46
  9. Ronghua Zhang · 3 shared papers, 2020–2024 · strength 0.38
  10. Lei You · 2 shared papers, 2020–2021 · strength 0.27
  11. Jorg H. Kleeff · 2 shared papers, 2020–2024 · strength 0.26
  12. Wenhu Zhou · 1 shared paper, 2024 · strength 0.23
  13. Aiping Huang · 1 shared paper, 2024 · strength 0.23
  14. Xiang Zhang · 2 shared papers, 2020–2021 · strength 0.20
  15. Qiaofei Liu · 2 shared papers, 2020–2021 · strength 0.20
  16. Huanwen Wu · 2 shared papers, 2020–2021 · strength 0.20
  17. Jingkai Liu · 2 shared papers, 2020–2021 · strength 0.20
  18. Wenming Wu · 1 shared paper, 2022 · strength 0.20
  19. Junya Peng · 1 shared paper, 2024 · strength 0.18
  20. Quan Liao · 1 shared paper, 2024 · strength 0.18
  21. Xianlin Han · 1 shared paper, 2021 · strength 0.14
  22. Li Zhou · 1 shared paper, 2020 · strength 0.09
  23. Boju Pan · 1 shared paper, 2020 · strength 0.09
  24. Weibin Wang · 1 shared paper, 2020 · strength 0.09
  25. Menghua Dai · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.